Canada has stopped the use of the Oxford/AstraZeneca vaccine against coronavirus for people under the age of 55 due to the risk of blood clotting as Associated Press reported citing the National Advisory Committee on Immunization (NACI).
“The NACI recommends not to use AstraZeneca vaccine for vaccination of people younger than 55 until we get more data on immune thrombocytopenic purpura caused by the vaccine,” the message said.
Vice-chair of the NACI Shelley Deeks stated that there is substantial uncertainty about the benefit of providing AstraZeneca Covid-19 vaccines to adults under 55 given the potential risks.
She specified that according to the new data from Europe, the risk of blood clots is now potentially as high as one in 100,000, much higher than the one in one million risks believed before.
According to her, the majority of the Europeans who got blood clots after the AstraZeneca vaccine were women at the age under 55 and the death rate among them reaches 40%.
This information was confirmed by a representative of Manitoba’s Vaccine Implementation Task Force. He noted that despite the finding that there was no increased risk of blood clots overall related to AstraZeneca in Europe, a rare but very serious side effect has been seen primarily in young women in Europe.
In Norway, three medics were hospitalized with blood clots. While a woman died after AstraZeneca shot in Croatia. In Spain, a 43-year-old teacher, who had never pathologies earlier, was vaccinated by AstraZeneca and died from cerebral hemorrhage.
However, the EMA does not have evidence that Oxford/AstraZeneca vaccine from Covid-19 might cause thrombosis; while the WHO recommended to continue vaccination with AstraZeneca drug. The organization believes this vaccine has more good than harm.